-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

Benzinga·09/15/2026 12:49:16
Listen to the news
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.